A5031211618- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Musculoskeletal pain and rehabilitation
- Chronic Lymphocytic Leukemia Research
- Spine and Intervertebral Disc Pathology
- Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Bone and Joint Diseases
- Inflammatory Bowel Disease
- Pregnancy and Medication Impact
- Immunodeficiency and Autoimmune Disorders
- Shoulder Injury and Treatment
- Biosimilars and Bioanalytical Methods
- Osteoarthritis Treatment and Mechanisms
- Clinical practice guidelines implementation
- Infectious Diseases and Tuberculosis
- Bone health and treatments
- Health, Medicine and Society
- Health Systems, Economic Evaluations, Quality of Life
- Spinal Hematomas and Complications
- Musculoskeletal synovial abnormalities and treatments
Centre Hospitalier Universitaire de Tours
2015-2024
Université de Tours
2015-2024
Centre National de la Recherche Scientifique
2011-2024
Assistance Publique – Hôpitaux de Paris
2011-2024
Hôtel-Dieu de Paris
2024
Center for Rheumatology
2024
Thion Medical (France)
2007-2022
Clinical Investigation Center Plurithematic Tours
2008-2021
Hôpital Armand-Trousseau
1996-2021
Sorbonne Université
1996-2021
Abstract Objective Tuberculosis (TB) is associated with anti–tumor necrosis factor (anti‐TNF) monoclonal antibody (mAb) therapy, but whether this association drug‐specific remains a concern. Our objective was to describe cases of TB anti‐TNF mAb identify risk factors, and estimate the incidence. Methods We conducted an incidence study case–control analysis investigate newly diagnosed use agents. As part French Research Axed on Tolerance Biotherapies (RATIO) registry, for 3 years we collected...
To evaluate the clinical response, safety, and tolerability of a single intraarticular injection anakinra in patients with symptomatic osteoarthritis (OA) knee.Patients OA knee were enrolled multicenter, double-blind, placebo-controlled study randomized 2:1:2 to receive placebo, 50 mg, or 150 mg their knee. Patients evaluated for 12 weeks postinjection. The primary end point was change Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) score from baseline week 4. Safety...
To determine prognostic factors of radiologic damage and progression in early rheumatoid arthritis (RA).A cohort 191 patients with RA whose disease duration was shorter than 1 year were prospectively followed up for 3 years. Radiologic scores (as determined by Sharp's method, modified van der Heijde) used as outcome measures. Numerous baseline clinical, laboratory, genetic, radiographic data obtained.The change the total score over years a mean +/- SD increase 6.1 6.2. observed 71 172 whom...
The primary objective was to compare a single, 6 ml, intra-articular injection of hylan G-F 20 with placebo in patients symptomatic knee osteoarthritis. safety repeat also assessed. Patients osteoarthritis pain were randomly assigned arthrocentesis plus ml either or prospective, double-blind (one injector/one blinded observer) study. evaluated at 4, 8, 12, 18 and 26 weeks post-injection. outcome criterion change from baseline over Western Ontario McMaster Universities (WOMAC) Osteoarthritis...
To evaluate the efficacy and safety of rituximab in patients with primary Sjögren's syndrome (pSS).The AutoImmune Rituximab registry has included 86 pSS treated rituximab, prospectivey followed up every 6 months for 5 years.Seventy-eight (11 men, 67 women), who already had at least one follow-up visit, were analysed. Median age was 59.8 years (29-83), median duration disease 11.9 (3-32). Indications treatment systemic involvement 74 only severe glandular four patients. The European Syndrome...
<h3>OBJECTIVES</h3> Matrix metalloproteinases (MMPs) are thought to be major mediators of cartilage destruction. Osteoarthritis (OA) is characterised by degradation. This study explores gene expression three MMPs in articular chondrocytes during the histological development lesion OA. <h3>METHODS</h3> Biopsy specimens human normal and OA cartilage, classified into four grades on basis histology, were probed for 1, 3, 9 using <sup>35</sup>S-labelled cDNA probes. The signal was measured at...
A proportion of patients receiving infliximab have antibodies toward (ATI), which are associated with increased risk infusion reaction and reduced response to treatment. We studied the association concentration at treatment initiation development ATI as well presence maintenance infliximab. All rheumatoid arthritis (RA) or spondyloarthritis (SpA) beginning in December 2005 were retrospectively followed until January 2009 discontinuation. Trough serum concentrations measured each visit. The...
Rituximab, a monoclonal antibody specifically targeting CD20, induces B cell depletion and is effective in the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate whether routine monitoring lymphocyte subpopulations, especially T cells, may be useful patients receiving rituximab for RA.We examined data on all RA between July 2007 November 2012 our center. Peripheral blood CD3+, CD4+, CD8+, CD3-CD56+, CD19+ counts before during first course were measured by flow...
<h3>Importance</h3> Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact COVID-19 among individuals with IMIDs who receiving TNF remains insufficiently understood. <h3>Objective</h3> To examine association between receipt inhibitor monotherapy and risk COVID-19–associated hospitalization or death compared other commonly immunomodulatory...
<h3>Objective</h3> To evaluate the efficacy of tocilizumab, an antibody against IL-6 receptor, in patients with hand osteoarthritis. <h3>Methods</h3> This was a multicentre, 12-week, randomised, double-blind, placebo-controlled study from November 2015 to October 2018. Patients symptomatic osteoarthritis (pain ≥40 on 0–100 mm visual analogue scale (VAS) despite analgesics and non-steroidal anti-inflammatory drugs; at least three painful joints, Kellgren-Lawrence grade ≥2) were randomised...
Objectives: To evaluate the effectiveness of adalimumab in patients with psoriatic arthritis (PsA) and identify predictors good clinical response for joint skin lesions. Methods: Patients received 40 mg every other week addition to standard therapy this prospective, 12-week, open-label, uncontrolled study. Four definitions were used: ⩾50% improvement American College Rheumatology criteria (ACR50), according European League Against Rheumatism (EULAR) guidelines, a ⩾3-grade Physician Global...